|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,404 INR | +0.36% |
|
+4.82% | +12.66% |
| May. 17 | Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director | CI |
| May. 17 | Indian Equities Extend Gains on Friday, Led by Real Estate, Auto and Metal Names | MT |
BENGALURU (Reuters) - Cipla, India's third-largest generic drugmaker by sales, reported fourth-quarter profit above expectations on Friday, driven by strong sales in its key U.S. and domestic markets.
The company reported a 78.5% increase in net profit to 9.39 billion rupees ($112.5 million) for the quarter ended March 31, beating analysts' estimate of 8.11 billion rupees as per LSEG data.
($1 = 83.4875 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,404 INR | +0.36% | +4.82% | 13.61B | ||
| 782.5 USD | +1.62% | +3.16% | 693B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +12.66% | 13.61B | |
| +21.63% | 44.12B | |
| +22.99% | 22.71B | |
| +18.22% | 15.15B | |
| +60.18% | 13.34B | |
| -8.35% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B | |
| +6.11% | 4.77B |
CIPLA LIMITED 
